Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome.
Ninety-five household contacts (aged 2 months to 73 years) of patients with enteropathic hemolytic-uremic syndrome (HUS) were investigated for the presence of immunoglobulin (Ig) G antibodies to Shiga toxins Stx2 and Stx1 by Western blot assay. Thirty-one percent of the household contacts and 19% of 327 controls had anti-Stx2 IgG (heavy and light chain [H + L]), 5 and 8%, respectively, had anti-Stx1 IgG (H + L), and 3 and 2%, respectively, had both anti-Stx2 and anti-Stx1 IgG (H + L). The incidence of infections with Stx-producing Escherichia coli (STEC) was determined based on the following diagnostic criteria: STEC isolation, detection of stx gene sequences, free fecal Stx in stool filtrates, and serum IgM antibodies against E. coli O157 lipopolysaccharide. Evidence of STEC infection was observed in 25 household contacts, of whom 18 (72%) were asymptomatic and represented a potential source of infection. Six of 13 (46%) household contacts with Stx2-producing E. coli O157:H7 in stool culture developed anti-Stx2 IgG (H + L), compared to 71% of Stx2-associated HUS cases. In individuals showing anti-Stx2 IgG (H + L), the antibody response was directed against the B subunit in 69% of household contacts and 71% of controls, in contrast to 28% of HUS patients. In this investigation controls had a significant increase of the median of IgM antibodies to O157 lipopolysaccharide (LPS) with age, up to the fifth decade. The lack of disease in household contacts with B subunit-specific antibodies, as well as the significantly higher median of anti-O157 LPS IgM antibodies in controls beyond 4.9 years of age, suggests a protective role for anti-Stx and anti-O157 LPS antibodies.
Ludwig
Kerstin
K
Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Hamburg-Eppendorf, Universität Hamburg, Martinistrasse 52, 20246 Hamburg, Germany. kludwig@uke.uni-hamburg.de
Sarkim
Volkan
V
Bitzan
Martin
M
Karmali
Mohamed A
MA
Bobrowski
Christoph
C
Ruder
Hans
H
Laufs
Rainer
R
Sobottka
Ingo
I
Petric
Martin
M
Karch
Helge
H
Müller-Wiefel
Dirk E
DE
D000293:Adolescent; D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood*; D000917:Antibody Formation; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D004927:Escherichia coli Infections / Q000175:diagnosis* / Q000635:transmission; D019453:Escherichia coli O157 / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity*; D005243:Feces / Q000382:microbiology; D005798:Genes, Bacterial; D005838:Genotype; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology / Q000382:microbiology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007223:Infant; D008875:Middle Aged; D012703:Serotyping / Q000379:methods; D022622:Shiga Toxin 1 / Q000096:biosynthesis / Q000276:immunology; D022641:Shiga Toxin 2 / Q000096:biosynthesis* / Q000276:immunology
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D022622:Shiga Toxin 1; D022641:Shiga Toxin 2